UCB and Ariceum Therapeutics Partner to Discover New Treatments for Immune-Related Diseases and Cancer
UCB and Ariceum Collaborate to Accelerate Drug Discovery UCB’s Expertise in Macrocyclic Peptide Discovery UCB, a leading biopharmaceutical company, is known for its expertise in macrocyclic peptide discovery. They have developed a proprietary mRNA-display platform called ExtremeDiversity™, which allows for the rapid and efficient identification of novel peptides with therapeutic potential. This cutting-edge technology has…